ArticleObesity surgery2026
Rapid Recurrent Weight Gain Within Two Years of Sleeve Gastrectomy: Clinical Predictors and Metabolic Consequences.
Article in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to identify risk factors for rapid recurrent weight gain (RRWG), defined as ≥ 20% regain from the weight loss 1 year postoperatively within 2 years after laparoscopic sleeve gastrectomy (LSG). In this retrospective cohort study, we analyzed 201 consecutive adults who underwent LSG, with weight recorded preoperatively and at 3, 6, 12, and 24 months postoperatively, and with extended follow-up to 5 years. Laboratory parameters, comorbidities, psychological evaluations, and medication use were also assessed. The median preoperative body mass index (BMI) was 39.4 kg/m². The median total body weight loss (TBWL) was 28.6% at 6 months, 34.4% at 1 year, and 32.9% at 2 years. Although weight loss outcomes were comparable between groups at 1 year, by 2 years the RRWG group showed significantly lower excess body weight loss (EBWL) and TBWL, as well as fewer patients achieving EBWL ≥ 50% (P < 0.001). Mid-term follow-up revealed persistently higher recurrence rates in the RRWG group at 3-4 years, with a continuing trend at 5 years. Compared with the maintained weight loss (MW) group, RRWG patients demonstrated a higher prevalence of diabetes (26.3% vs. 7.1%, P = 0.017), greater worsening of dyslipidemia (57.9% vs. 25.3%, P = 0.006), and lower rates of hypertension remission (46.2% vs. 62.5%, P = 0.002) at 24 months. Multivariable analysis identified preoperative BMI < 37.4 (aOR = 5.036, P = 0.001), and TBWL at 12 months < 25% (aOR = 4.930, P = 0.036) as independent predictors of RRWG. Lower preoperative BMI, and suboptimal 12-month weight loss independently predicted RRWG after LSG. Early identification of high-risk patients is essential to optimize long-term outcomes after LSG.
Indexed as
Identifiers
41739432What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.